Pay in 4 interest-free payments of $6.56 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Do inform your healthcare provider about any history of pancreatitis, gallbladder disease, or severe gastrointestinal disease (such as gastroparesis) before starting tirzepatide
Slowly but surely with my GLP-1 ;) @joinmochisocials @drmyramochi @myrajoinmochi #joinmochi #mochihealth #mochipartner @joinmochisocials @drmyramochi @myrajoinmochi #joinmochi #mochihealth #mochipartner Actually compound glp-1s makes life saving medications more available and more affordable for everyone
Also useful for those with scarring alopecia or folliculitis-related thinning where tissue repair is a priority
discontinued CJC-1295 (DAC) Not FDA-approved Feature Phase III Trial Data Tesamorelin Yes (n=816 pooled) Sermorelin No adult Phase III VAT datasets CJC-1295 (DAC) No Feature Visceral Fat Reduction Tesamorelin 15-20% at 26 weeks Sermorelin Not formally studied in RCTs CJC-1295 (DAC) Not formally studied in RCTs Feature Liver Fat Reduction Tesamorelin 32% at 12 months (NAFLD trial) Sermorelin Not studied CJC-1295 (DAC) Not studied Feature Typical Research Dose Tesamorelin 2 mg daily Sermorelin 200-300 mcg nightly CJC-1295 (DAC) 1-2 mg weekly Feature Unique Advantage Tesamorelin Only FDA-approved GHRH with deepest trial evidence Sermorelin Longest historical track record CJC-1295 (DAC) Weekly dosing convenience Tesamorelin is the only GHRH peptide with active FDA approval and validated Phase III visceral-fat data
US$ 23.20
US$ 29.16
US$ 25.02
US$ 25.55
US$ 25.72
US$ 28.06
US$ 21.33
US$ 21.95
